$ABIO News
Last published 2y ago
- 2y agoABIOARCA biopharma Announces Completion of Merger with Oruka Therapeutics and Implementation of Reverse Stock SplitGlobeNewswireWESTMINSTER, Colo., Aug. 29, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO) ("ARCA") today announced completion of the merger with Oruka Therapeutics, Inc. ("Oruka") following ARCA's successful receipt of
- 2y agoABIOARCA biopharma Provides Update Regarding Special Dividend Amount in Connection with the Proposed Merger with Oruka TherapeuticsGlobeNewswireWESTMINSTER, Colo., Aug. 26, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO) ("ARCA") today announced an update to the previously announced final amount of the special cash dividend (the "Special
- 2y agoABIOARCA biopharma Announces 1-for-12 Reverse Stock Split in Connection with the Proposed Merger with Oruka TherapeuticsGlobeNewswireWESTMINSTER, Colo., Aug. 23, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO) ("ARCA") today announced that its Board of Directors (the "Board") has approved a reverse stock split of ARCA's common stock at a
- 2y agoABIOARCA biopharma Declares Special Dividend in Connection with the Proposed Merger with Oruka TherapeuticsGlobeNewswireSpecial dividend estimated to be $1.59 per share Payment of special dividend conditioned upon ARCA stockholder approval of the Proposed Merger with Oruka WESTMINSTER, Colo., Aug. 16, 2024 (GLOBE NEWSWIRE) -- ARCA
- 2y agoABIOARCA biopharma Announces Second Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewswireWESTMINSTER, Colo., Aug. 01, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO), (the "Company") a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies
- 2y agoABIOSQSPSSBHMNFKuehn Law Encourages ABIO, SQSP, SSB, and HMNF Investors to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may...
- 2y agoABIOARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewswireARCA biopharma and Oruka Therapeutics announce Merger AgreementARCA biopharma appoints Thomas Keuer as President WESTMINSTER, Colo., April 25, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO), (the
- 2y agoABIOMODNSWAVWIREKuehn Law Encourages WIRE, ABIO, MODN, and SWAV Investors to Contact Law FirmGlobeNewswireNEW YORK, April 22, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures
- 2y agoKTRAABIOSWAVNSKuehn Law Encourages KTRA, ABIO, SWAV, and NS Investors to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may...
- 2y agoABIOARCA biopharma and Oruka Therapeutics Announce Merger AgreementGlobeNewswireMerger to create a company focused on advancing Oruka's portfolio of novel biologics that aim to redefine the standard of care for patients with chronic skin diseases Oruka, the third company founded based on assets
- 2y agoABIOARCA biopharma Announces 2023 Financial ResultsGlobeNewswireCompany is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options WESTMINSTER, Colo., Feb. 01, 2024 (GLOBE NEWSWIRE) -- ARCA
- 3y agoABIOARCA biopharma Announces Third Quarter 2023 Financial ResultsGlobeNewswireCompany is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options WESTMINSTER, Colo., Oct. 18, 2023 (GLOBE NEWSWIRE) -- ARCA
- 3y agoABIOARCA biopharma Announces Second Quarter 2023 Financial ResultsGlobeNewswireCompany is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options WESTMINSTER, Colo., July 21, 2023 (GLOBE NEWSWIRE) -- ARCA
- 3y agoABIOARCA biopharma Announces First Quarter 2023 Financial ResultsGlobeNewswireWESTMINSTER, Colo., April 24, 2023 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for
- 3y agoABIOARCA biopharma Announces 2022 Financial Results and Provides Corporate UpdateGlobeNewswireWESTMINSTER, Colo., Feb. 24, 2023 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for
- 3y agoABIOJames Flynn Joins ARCA biopharma Board of DirectorsGlobeNewswireWESTMINSTER, Colo., Dec. 19, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO) today announced that James Flynn has joined its Board of Directors. "We are pleased to welcome James Flynn to our Board," said
- 4y agoABIOARCA biopharma Announces Third Quarter 2022 Financial ResultsGlobeNewswireWESTMINSTER, Colo., Oct. 28, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for
- 4y agoABIOARCA biopharma Announces Second Quarter 2022 Financial ResultsGlobeNewswireCompany is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options WESTMINSTER, Colo., Aug. 02, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO), a bio
- 4y agoABIOJacob Ma-Weaver Joins ARCA biopharma Board of DirectorsGlobeNewswireWESTMINSTER, Colo., June 21, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO) today announced that Jacob Ma-Weaver has joined its Board of Directors. "We are pleased to welcome Jacob Ma-Weaver, the managing member of ARCA's largest shareh
- 4y agoABIOARCA biopharma Retains Ladenburg Thalmann to Support Strategic Options ReviewGlobeNewswireWESTMINSTER, Colo., May 05, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO) today announced that it has retained Ladenburg Thalmann & Co. Inc. to act as its financial advisor. In April 2022, the Board of Directors established a Special C
- 4y agoABIOARCA biopharma Announces First Quarter 2022 Financial ResultsGlobeNewswireCompany is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options WESTMINSTER, Colo., May 02, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO), a bi
- 4y agoABIOARCA biopharma Establishes Special Committee of the Board of DirectorsGlobeNewswireWESTMINSTER, Colo., April 18, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that
- 4y agoABIOARCA biopharma Reports Topline Results for ASPEN-COVID-19 Phase 2b Clinical TrialGlobeNewswireFor the entire cohort of COVID-19 hospitalized patients, the pooled lower and higher rNAPc2 dose groups demonstrated a reduction compared to baseline in D-dimer levels of 16.8% versus 11.2% for standard of care heparin which was not statistically signif
- 4y agoABIOARCA biopharma Announces 2021 Financial Results and Provides Corporate UpdateGlobeNewswireWESTMINSTER, Colo., March 14, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported 2021
- 4y agoABIOData on Gencaro Impact on Prevention of Bradycardia Published in Heart Rhythm O2GlobeNewswireClinically important bradycardia is common in heart failure (HF) patients with persistent or paroxysmal atrial fibrillation (AF) In a Phase 2B clinical trial, the prevalence of clinically important bradycardia was statistically significantly lower for
- 4y agoABIOARCA biopharma Announces Completion of Enrollment in Phase 2b ASPEN-COVID-19 Clinical Trial Evaluating rNAPc2 as a Potential Treatment for Patients Hospitalized with COVID-19GlobeNewswireTopline readout of clinical trial results anticipated in first quarter of 2022 WESTMINSTER, Colo., Dec. 02, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO), a biopharmaceutical company applying a precision medicine approach to developi
- 5y agoABIOARCA biopharma to Present at the Q4 Virtual Investor Summit on November 17thGlobeNewswireWESTMINSTER, Colo., Nov. 09, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that
- 5y agoAAZZFABIOACOGFACST+81Investor Summit Group Provides Update on Upcoming Q4 Virtual SummitGlobeNewswireNEW YORK, Nov. 05, 2021 (GLOBE NEWSWIRE) -- The Investor Summit Group, widely recognized for its reputation as the host of North America's largest independent investor conferences, will be hosting the upcoming Q4 Virtual Summit on November 16-17. The e
- 5y agoABIOARCA biopharma Announces Third Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewswireOn-going Phase 2b clinical trial (ASPEN-COVID-19) evaluating rNAPc2 as a potential treatment for COVID-19 DSMC interim analysis of safety and efficacy data from ASPEN-COVID-19 completed with recommendation to continue trial to completion with no modifi
- 5y agoABIOASPEN-COVID-19 Data and Safety Monitoring Committee Recommends Continuing Phase 2b Clinical Trial to Completion Based on Interim Analysis of Efficacy and Safety DataGlobeNewswireEnrollment completion anticipated by year end 2021 Topline data anticipated in first quarter of 2022 WESTMINSTER, Colo., Oct. 28, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO), a biopharmaceutical company applying a precision medici
- 5y agoABIOARCA biopharma Announces Enrollment of First International Patient in Phase 2b Clinical Trial Evaluating rNAPc2 as a Potential Treatment for COVID-19GlobeNewswireFirst international patient enrolled in Brazil Trial approximately 75% enrolled rNAPc2 development focused on unmet need for treatments in hospitalized COVID-19 patients Topline trial data anticipated in the fourth quarter of 2021 WESTMINST
- 5y agoABIOARCA biopharma to Present at the Q3 Virtual Investor Summit on August 18thGlobeNewswireWESTMINSTER, Colo., Aug. 16, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that
- 5y agoABIOARCA biopharma Announces Submission of PCT Patent Application for the Treatment of Coronavirus Infection and Associated Coagulopathy with rNAPc2GlobeNewswireWESTMINSTER, Colo., Aug. 09, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that
- 5y agoABIOARCA biopharma Announces Second Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewswirePhase 2b clinical trial evaluating rNAPc2 as a potential treatment for COVID-19 expanded to South America Topline data anticipated in the fourth quarter of 2021 WESTMINSTER, Colo., Aug. 04, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:AB
- 5y agoABIOGencaro Atrial Fibrillation Phase 2B Results Selected for Publication in Circulation: Arrhythmia and ElectrophysiologyGlobeNewswireAnalysis in full patient cohort shows Gencaro effect compared to standard of care In the GENETIC-AF entire cohort of heart failure patients treated with Gencaro, compared to patients treated with metoprolol succinate (TOPROL-XL), experienced: a 36% r
- 5y agoABIOARCA biopharma Provides Update on ASPEN-COVID-19 Phase 2b Clinical Trial Evaluating rNAPc2 as a Potential Treatment for COVID-19GlobeNewswirerNAPc2 development focused on unmet need for treatments in hospitalized COVID-19 patients Trial expanded to South America, with regulatory approvals for Argentina and Brazil Target trial enrollment increased to 160 patients Topline trial data anticip
- 5y agoABIOARCA biopharma to Present at Access to Giving Virtual Investor Conference on July 13thGlobeNewswireWESTMINSTER, Colo., July 09, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that
- 5y agoABIOARCA biopharma Announces rNAPc2 COVID-19 Patent Assignment AgreementGlobeNewswireProvides exclusive world-wide patent rights to the use of rNAPc2 as a potential treatment for COVID-19 and other indications WESTMINSTER, Colo., July 07, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO) today announced it has entered in
- 5y agoABIOARCA biopharma Announces First Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewswireTopline data from Phase 2b clinical trial evaluating rNAPc2 as a potential treatment for COVID-19 anticipated in the third quarter of 2021 WESTMINSTER, Colo., May 11, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO), a biopharmaceutical
- 5y agoABIOChristopher Graybill Joins ARCA as Vice President, Clinical DevelopmentGlobeNewswireWESTMINSTER, Colo., May 05, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that C
- 5y agoABIOARCA biopharma Announces C. Jeff Dekker to be Appointed Chief Financial OfficerGlobeNewswireWESTMINSTER, Colo., May 03, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced C. Jef
- 5y agoABIOARCA biopharma Announces 2020 Financial Results and Provides Corporate UpdateGlobeNewswireTopline data from Phase 2b clinical trial evaluating rNAPc2 as a potential treatment for COVID-19 anticipated in the third quarter of 2021 New patent issued by USPTO for use of Gencaro in treating...
- 5y agoABIOARCA biopharma Announces First Patients Enrolled in ASPEN-COVID-19 Phase 2b Clinical Trial Evaluating rNAPc2 (AB201) as a Potential Treatment for COVID-19GlobeNewswirerNAPc2 development focused on unmet need for treatments in hospitalized COVID-19 patients, including after availability of vaccinesrNAPc2 is the only novel compound being developed for COVID-19...
- 5y agoABIOARCA biopharma Announces Location Change for 2020 Annual Meeting of StockholdersGlobeNewswireWESTMINSTER, Colo., Dec. 09, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), today announced that its 2020 Annual Meeting of Stockholders, scheduled for Thursday, December 10, 2020 at...
- 5y agoABIOAB201 Development as a Potential Treatment for COVID-19 Receives U.S. FDA Fast Track DesignationGlobeNewswireDevelopment addresses need for treatments for patients hospitalized with COVID-19 whether vaccines are available or notAB201 is the only novel compound being developed for COVID Associated...
- 6y agoABIOARCA biopharma Announces Third Quarter 2020 Financial Results and Provides Corporate UpdateGlobeNewswireInitiation of Phase 2b clinical trial evaluating AB201 as a potential treatment for COVID19 anticipated in fourth quarterTopline data from trial anticipated Q2 2021 WESTMINSTER, Colo., Nov. 02,...
- 6y agoABIOARCA biopharma Announces FDA Approval of IND Application for AB201 as a Potential Treatment for COVID-19GlobeNewswireInitiation of Phase 2b clinical trial anticipated in Q4 2020Trial to enroll approximately 100 patients hospitalized with COVID-19Topline data anticipated Q2 2021 WESTMINSTER, Colo., Oct. 07, 2020 ...
- 6y agoABIOARCA biopharma Announces Promotion of Chief Medical Officer and Vice President, Regulatory Affairs & QualityGlobeNewswireWESTMINSTER, Colo., Oct. 05, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted...
- 6y agoABIOARCA biopharma Announces Submission of IND Application to U.S. FDA for AB201 as a Potential Treatment for COVID-19GlobeNewswireWESTMINSTER, Colo., Sept. 21, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted...
- 6y agoABIONew patent application published for: Methods and Compositions Involving Bucindolol for the Treatment of Atrial FibrillationUS Patent Applications (USPTO)